Related Experiment Video
Updated: Jan 11, 2026
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Association between maternal asthma and impaired infant lung function is diminished by inhaled corticosteroid use in
Gabriela Martins Costa Gomes1,2, Adam M Collison1,2, Wilfried J J Karmaus3
1Asthma and Breathing Research Program, The University of Newcastle Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
Background:
Infants of asthmatic mothers have reduced lung function in early life for reasons that remain to be defined. The association between inhaled corticosteroid (ICS) use during pregnancy and lung function in the offspring has not been investigated.
Objectives:
To investigate the association between ICS use during pregnancy and infant lung function.
Methods:
Multivariable regression analysis of infant lung function at 4-6 weeks (tidal breathing flow volume loops and functional residual capacity (FRC)) associated with use of ICS during pregnancy.
Results:
Among infants born to asthmatic mothers, the ratio of time to peak tidal expiratory flow to expiratory time (tPTEF:tE), corrected for end-expiratory lung volume (FRC), was improved in offsprings whose mothers used ICS during pregnancy compared with those who did not (n=161 ICS use vs n=25 no ICS use; coefficient 0.06 /mL, 95% CI 0.01 to 0.11, p=0.014). Compared with a control group of infants born to non-asthmatic mothers, there was a lower tPTEF:tE to FRC ratio in infants born to asthmatic mothers without ICS use (n=46 no asthma vs n=25 asthma no ICS use; coefficient -0.08 /mL, 95% CI -0.01 to -0.02, p=0.012) but not in infants born to asthmatic mothers with ICS use (n=46 no asthma vs n=161 asthma ICS use; coefficient -0.02 /mL, 95% CI -0.06 to 0.03, p=0.453).
Conclusions:
The association between maternal asthma and impaired infant lung function diminished in infants whose mothers used ICS during pregnancy.
Trial Registration:
Australian New Zealand Clinical Trials Registry ACTRN12613000202763.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
01:29Asthma-I: Introduction
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.